Earnings results expected in 37 days
Summary
4ABBV closed Friday higher at €167.2, an increase of 0.6% from Thursday's close, completing a monthly decrease of -2.68% or €4.6. Over the past 12 months, 4ABBV stock lost -3.83%.
4ABBV pays dividends to its shareholders, with the most recent payment made on May 15, 2025. The next estimated payment will be in In 1 month on Aug 15, 2025 for a total of €1.64.
The last earnings report, released on Apr 24, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.01%, based on the last three reports. The next scheduled earnings report is due on Jul 23, 2025.
The stock of the company had never split.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track 4ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
4ABBV Chart
Here's Why AbbVie (ABBV) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks | 2 hours ago
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
Zacks | 3 hours ago
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
NORTH CHICAGO, Ill. , June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772.
Prnewswire | 4 hours ago
ABBVIE Dividends
 ABBV In 4 weeks Estimated | Quarterly | $1.64 Per Share |
| ABBV 2 months ago Paid | Quarterly | $1.64 Per Share |
| ABBV 5 months ago Paid | Quarterly | $1.64 Per Share |
| ABBV 8 months ago Paid | Quarterly | $1.55 Per Share |
| ABBV 11 months ago Paid | Quarterly | $1.55 Per Share |
| ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
ABBVIE Earnings
| 23 Jul 2025 (37 Days) Date | | - Cons. EPS | - EPS |
| 24 Apr 2025 Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
| 30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
| 25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
| ABBV In 4 weeks Estimated | Quarterly | $1.64 Per Share |
| ABBV 2 months ago Paid | Quarterly | $1.64 Per Share |
| ABBV 5 months ago Paid | Quarterly | $1.64 Per Share |
| ABBV 8 months ago Paid | Quarterly | $1.55 Per Share |
| ABBV 11 months ago Paid | Quarterly | $1.55 Per Share |
| ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
| 23 Jul 2025 (37 Days) Date | | - Cons. EPS | - EPS |
| 24 Apr 2025 Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
| 30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
| 25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
ABBVIE (4ABBV) FAQ
What is the stock price today?
The current price is €167.20.
On which exchange is it traded?
ABBVIE is listed on NYSE.
What is its stock symbol?
The ticker symbol is 4ABBV.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
What is the earnings per share?
The EPS is 0.
When is the next earnings date?
The next earnings report will release on Jul 23, 2025.
Has ABBVIE ever had a stock split?
No, there has never been a stock split.
ABBVIE Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Michael CPA CEO | XMIL Exchange | US00287Y1091 ISIN |
| US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
Overview
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.
Products and Services
- Humira: A therapeutic injection for various autoimmune diseases, including intestinal Behçet's disease and pyoderma gangrenosum.
- Skyrizi: Prescribed for patients with moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease, focusing on improving skin health.
- Rinvoq: Targets multiple conditions such as rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and several gastrointestinal diseases.
- Imbruvica: An oral medication for adults with various blood cancers, marking significant advancements in oncology.
- Epkinly and Elahere: Treatments tailored for different forms of lymphoma and cancer, showcasing AbbVie's innovations in targeted therapies.
- Venclexta/Venclyxto: Offers hope for patients battling blood cancers, through a regimen that interferes with cancer cell survival.
- Aesthetic Products: A range of facial injectables, plastics and regenerative medicine, body contouring, and skincare offerings that cater to aesthetic needs.
- Botox Therapeutic: Beyond cosmetic applications, this product is utilized for various therapeutic purposes, enhancing patient care.
- Vraylar: A medication designed to address depressive disorder, contributing to mental health treatment options.
- Duopa and Duodopa: These formulations provide relief for patients with advanced Parkinson's disease, improving quality of life.
- Ubrelvy and Qulipta: Target the acute treatment of migraine in adults, including both episodic and chronic forms.
- Ozurdex: An ocular implant designed to treat eye diseases, emphasizing AbbVie's contribution to ophthalmology.
- Lumigan/Ganfort and Alphagan/Combigan: Aimed at reducing intraocular pressure in conditions like open-angle glaucoma or ocular hypertension.
- Restasis: Helps increase tear production, addressing the needs of patients with dry eye disease.
- Mavyret/Maviret: Administered for the treatment of chronic hepatitis C virus (HCV) infection, representing a breakthrough in HCV treatment.
- Creon: A pancreatic enzyme therapy essential for patients with pancreatic insufficiency, aiding digestion.
- Lupron: Utilized for treating advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids-related anemia.
- Linzess/Constella: Offers relief for irritable bowel syndrome with constipation and chronic idiopathic constipation.
- Synthroid: A synthetic thyroid hormone used to treat hypothyroidism, ensuring thyroid hormone levels are balanced.
Contact Information
Address: 1 North Waukegan Road
Phone: 847 932 7900
Website: https://www.abbvie.com
2025 © Marketlog. All Rights Reserved.
